drugset / Trial / NCT01455246

Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis

NCT01455246 ↗

Phase 2/3 Terminated 32 enrolled University of Padova
RandomizedParallel-groupOpen-labelTreatment

Summary

Nosocomial spontaneous bacterial peritonitis (SBP) is frequently caused by multi drug resistant bacteria. Standard treatment of SBP could be ineffective. The aim of the study is to compare daptomycin + meropenem vs ceftazidime in the treatment of nosocomial SBP.

Timeline

Start
2010-10
Primary completion
2014-04
Completion
2014-07

Outcome

Outcome not reported

Stopped: “Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftazidime Small molecule 2 g Intravenous
Subject Daptomycin Other / unclassified 6 mg/kg —
Subject Meropenem Small molecule 0.5 g —
Subject Meropenem Small molecule 1 g —

Indications